Source comparison
Thymosin Alpha-1 vs Standard Lupus Treatments: Clinical Context Comparison
Prednisone Broad immunosuppression via glucocorticoid receptor Suppresses Tregs and effector cells equally High (opportunistic infections common) Dose-dependent toxicity Oral daily First-line for flare control; long-term use creates cumulative toxicity Hydroxy
This comparison does not assign a generated winner or score.
- Prednisone
- Broad immunosuppression via glucocorticoid receptor
- Suppresses Tregs and effector cells equally
- High (opportunistic infections common)
- Dose-dependent toxicity
- Oral daily
- First-line for flare control; long-term use creates cumulative toxicity
- Hydroxychloroquine
- TLR inhibition, reduces dendritic cell activation
- Minimal direct effect
- Low
- Safe long-term
- First-line maintenance; reduces flare frequency 50%
- Mycophenolate mofetil
- Purine synthesis inhibition, blocks B/T-cell proliferation
- Suppresses all lymphocytes including Tregs
- Moderate
- Requires monitoring
- Oral twice daily
- First-line for nephritis and severe organ involvement
- Belimumab
- Anti-BLyS monoclonal antibody, reduces B-cell survival
- Indirect: fewer B-cells means less Th2 skewing
- Low to moderate
- Safe
- IV infusion monthly
- FDA-approved adjunct; 30–40% response rate
- Thymosin alpha-1
- Enhances Treg differentiation, shifts dendritic cells to tolerogenic phenotype
- Directly increases Treg populations
- Low (preserves pathogen-specific immunity)
- No known renal toxicity
- Subcutaneous 2–3x weekly
- Experimental adjunct; not FDA-approved for lupus